CoChat

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

Open access
Luchini, Claudio, Paolino, Gaetano, Mattiolo, Paola, Piredda, Maria L., Cavaliere, Alessandro, Gaule, Marina, Melisi, Davide, Salvia, Roberto, Malleo, Giuseppe, Shin, Jae Il, Cargnin, Sarah, Terrazzino, Salvatore, Lawlor, Rita T., Milella, Michele, Scarpa, Aldo · 2020 · Journal of Experimental & Clinical Cancer Research
Cited by 101

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases. The genetic landscape of KRAS wild type PDAC can be divided into three categories. The first is represented by tumors with an activated MAPK pathway due to BRAF mutation that occur in up to 4% of cases. The second includes tumors with microsatellite instability (MSI) due to defective DNA mismatch repair (dMMR), which occurs in about 2% of cases, also featuring a high tumor mutational burden. The third category is represented by tumors with kinase fusion genes, which marks about 4% of cases. While therapeutic molecular targeting of KRAS is an unresolved challenge,KRAS-wild type PDACs have potential options for tailored treatments, including BRAF antagonists and MAPK inhibitors for the first group, immunotherapy with anti-PD-1/PD-L1 agents for the MSI/dMMR group, and kinase inhibitors for the third group. This calls for a complementation of the histological diagnosis of PDAC with a routine determination of KRAS followed by a comprehensive molecular profiling of KRAS-negative cases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13046-020-01732-6

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 101

Metadata

Authors
Luchini, C., Paolino, G., Mattiolo, P., Piredda, M. L., Cavaliere, A., Gaule, M., Melisi, D., Salvia, R., Malleo, G., Shin, J. I., Cargnin, S., Terrazzino, S., Lawlor, R. T., Milella, M., & Scarpa, A.
Venue
Journal of Experimental & Clinical Cancer Research
Published
2020-10-28
Volume
39
Issue
1
Pages
227-227
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W3095252657
Cited by
101
References
16
FWCI
4.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. https://app.cochat.ai/papers/10.1186/s13046-020-01732-6
The paper
Luchini, C., Paolino, G., Mattiolo, P., Piredda, M. L., Cavaliere, A., Gaule, M., Melisi, D., Salvia, R., Malleo, G., Shin, J. I., Cargnin, S., Terrazzino, S., Lawlor, R. T., Milella, M., & Scarpa, A. (2020). KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-020-01732-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.